Patents by Inventor Zhenxi Zhang
Zhenxi Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11915793Abstract: The present disclosure relates to Fragile X Syndrome (FXS) clinical testing, and in particular to an FXS AGG interruption polymerase chain reaction (PCR) assay and an AGG interruption genotyping algorithm for implementation into clinical testing. Particularly, aspects are directed to obtaining raw data from the FXS assay performed on a sample, iteratively searching the raw data and identifying one or more AGG peaks on the first allele using a first set of search spaces determined based on an expected AGG peak size, determining a number of CGG repeats downstream of a final AGG interruption and a number of CGG repeats preceding a first AGG interruption on the first allele based on the one or more AGG peaks, and generating an AGG genotype for the first allele based on the number of CGG repeats downstream of the final AGG interruption and the number of CGG repeats preceding the first AGG interruption.Type: GrantFiled: January 29, 2021Date of Patent: February 27, 2024Assignee: Laboratory Corporation of America HoldingsInventors: Zhenxi Zhang, Matt Robinson, Patricia Okamoto
-
Publication number: 20230407398Abstract: Disclosed are methods and systems for detecting methylation of the Fragile X FMRI gene. In certain embodiments, the DNA is fragmented and then the assay uses methylation-specific immunoprecipitation to separate the genomic DNA into a methylated and an unmethylated fraction. In an embodiment, both fractions, along with the initial unfractionated DNA, are processed in parallel. In certain embodiments, the assay in performed on a plurality of samples using a multiwell plate. After resolution of the PCR products by capillary electrophoresis, a computerized custom calling tool may be used to qualitatively determine methylation status.Type: ApplicationFiled: February 9, 2023Publication date: December 21, 2023Inventors: Patricia Okamoto, Zhenxi Zhang
-
Publication number: 20220228216Abstract: The present disclosure relates to methods, compositions, and systems for detecting silent carriers of spinal muscular atrophy (SMA). In some embodiments, the invention comprises a method for identifying a subject as a silent carrier of SMA. The method may comprise obtaining a nucleic acid sample from a subject. The method may further comprise analyzing the nucleic acid sample, wherein analyzing the nucleic acid sample comprises detecting the presence or absence of a target gene amplification product. The method may further comprise characterizing the subject as a silent carrier of SMA if the target gene amplification product is present. Also disclosed are systems and kits for carrying out embodiments of the methods or using the compositions disclosed herein.Type: ApplicationFiled: January 14, 2022Publication date: July 21, 2022Inventors: Patricia Okamoto, Zhenxi Zhang
-
Publication number: 20210241850Abstract: The present disclosure relates to Fragile X Syndrome (FXS) clinical testing, and in particular to a FXS AGG interruption polymerase chain reaction (PCR) assay and an AGG interruption genotyping algorithm for implementation into clinical testing. Particularly, aspects are directed to obtaining raw data from the FXS assay performed on a sample, iteratively searching the raw data and identifying one or more AGG peaks on the first allele using a first set of search spaces determined based on an expected AGG peak size, determining a number of CGG repeats downstream of a final AGG interruption and a number of CGG repeats preceding a first AGG interruption on the first allele based on the one or more AGG peaks, and generating a AGG genotype for the first allele based on the number of CGG repeats downstream of the final AGG interruption and the number of CGG repeats preceding the first AGG interruption.Type: ApplicationFiled: January 29, 2021Publication date: August 5, 2021Inventors: Zhenxi Zhang, Matt Robinson, Patricia Okamoto
-
Publication number: 20160287689Abstract: The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce C. difficile toxin-neutralizing polyclonal immune globulin.Type: ApplicationFiled: January 4, 2016Publication date: October 6, 2016Inventors: William D. THOMAS, JR., Paul J. GIANNASCA, Zhenxi ZHANG, Wende LEI, Thomas P. MONATH
-
Patent number: 9226956Abstract: The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce C. difficile toxin-neutralizing polyclonal immune globulin.Type: GrantFiled: April 27, 2012Date of Patent: January 5, 2016Assignee: Sanofi Pasteur Biologics, LLCInventors: William D. Thomas, Jr., Paul J. Giannasca, Zhenxi Zhang, Wende Lei, Thomas P. Monath
-
Publication number: 20150030612Abstract: The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce C. difficile toxin-neutralizing polyclonal immune globulin.Type: ApplicationFiled: October 10, 2014Publication date: January 29, 2015Inventors: William D. THOMAS, JR., Paul J. GIANNASCA, Zhenxi ZHANG, Wende LEI, Thomas P. MONATH
-
Publication number: 20130177592Abstract: The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce C. difficile toxin-neutralizing polyclonal immune globulin.Type: ApplicationFiled: April 27, 2012Publication date: July 11, 2013Applicant: Sanofi Pasteur Biologics, LLCInventors: William D. Thomas, JR., Paul J. Giannasca, Zhenxi Zhang, Wende Lei, Thomas P. Monath
-
Publication number: 20070231336Abstract: The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce C. difficile toxin-neutralizing polyclonal immune globulin.Type: ApplicationFiled: May 30, 2007Publication date: October 4, 2007Applicant: Acambis Inc.Inventors: William Thomas, Paul Giannasca, Zhenxi Zhang, Wende Lei, Thomas Monath
-
Publication number: 20060029608Abstract: The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce C. difficile toxin-neutralizing polyclonal immune globulin.Type: ApplicationFiled: September 26, 2005Publication date: February 9, 2006Inventors: William Thomas, Paul Giannasca, Zhenxi Zhang, Wende Lei, Thomas Monath
-
Patent number: 6969520Abstract: The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce C. difficile toxin-neutralizing polyclonal immune globulin.Type: GrantFiled: December 16, 2003Date of Patent: November 29, 2005Assignee: Acambis Inc.Inventors: William D. Thomas, Jr., Paul J. Giannasca, Zhenxi Zhang, Wende Lei, Thomas P. Monath
-
Publication number: 20040126383Abstract: The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce C. difficile toxin-neutralizing polyclonal immune globulin.Type: ApplicationFiled: December 16, 2003Publication date: July 1, 2004Inventors: William D. Thomas, Paul J. Giannasca, Zhenxi Zhang, Wende Lei, Thomas P. Monath
-
Patent number: 6680168Abstract: The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce C. difficile toxin-neutralizing polyclonal immune globulin.Type: GrantFiled: March 22, 2001Date of Patent: January 20, 2004Assignee: Acambis, Inc.Inventors: William D. Thomas, Jr., Paul J. Giannasca, Zhenxi Zhang, Wende Lei, Thomas P. Monath
-
Publication number: 20010051153Abstract: The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce C. difficile toxin-neutralizing polyclonal immune globulin.Type: ApplicationFiled: March 22, 2001Publication date: December 13, 2001Inventors: William D. Thomas, Paul J. Giannasca, Zhenxi Zhang, Wende Lei, Thomas P. Monath
-
Patent number: 6214341Abstract: The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce C. difficile toxin-neutralizing polyclonal immune globulin.Type: GrantFiled: October 20, 1998Date of Patent: April 10, 2001Assignee: OraVaxInventors: William D. Thomas, Jr., Paul J. Giannasca, Zhenxi Zhang, Wende Lei, Thomas P. Monath
-
Patent number: 5919463Abstract: The invention features methods and compositions for inducing protective and/or therapeutic immune responses to an antigen in a mammal. In these methods, an antigen is administered to the mammal with a toxin of a Clostridium (e.g., C. difficile), or a fragment or derivative thereof having adjuvant activity.Type: GrantFiled: October 16, 1995Date of Patent: July 6, 1999Assignee: OraVax, Inc.Inventors: William D. Thomas, Jr., Thomas P. Monath, Zhenxi Zhang, Francisco Javier Torres-Lopez, Wende Lei, David M. Lyerly, James S. Moncrief